Experienced in Chronic Myelogenous Leukemia (CML)

Dr. Alan H. Bryce

Hematology Oncology | Oncology | Hematology
City Of Hope Medical Group Of Arizona LLC
14200 W Celebrate Life Way, 
Goodyear, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Chronic Myelogenous Leukemia (CML)
City Of Hope Medical Group Of Arizona LLC
14200 W Celebrate Life Way, 
Goodyear, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alan Bryce is a Hematologist Oncology specialist and an Oncologist in Goodyear, Arizona. Dr. Bryce is rated as an Experienced provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Melanoma, and Urothelial Cancer. Dr. Bryce is currently accepting new patients.

His clinical research consists of co-authoring 122 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in MN
Hospital Affiliations
Western Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

CITY OF HOPE MEDICAL GROUP OF ARIZONA LLC
14200 W Celebrate Life Way, Goodyear, AZ 85338

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Recruiting
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drugs: 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
Study Phase: Phase 1/Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor
RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor
Enrollment Status: Completed
Publish Date: November 12, 2024
Intervention Type: Other, Drug
Study Drug: Camostat mesilate
Study Phase: Phase 2
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Enrollment Status: Active_not_recruiting
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drug: PT-112
Study Phase: Phase 2
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2024
Intervention Type: Drug
Study Drugs: Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Study Phase: Phase 2
A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Biological, Drug
Study Drugs: PT-112, Avelumab
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma
Enrollment Status: Completed
Publish Date: January 02, 2020
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

122 Total Publications

Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review.
Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review.
Journal: medRxiv : the preprint server for health sciences
Published: May 05, 2025
Similar Doctors
Distinguished in Chronic Myelogenous Leukemia (CML)
Dr. Horst U. Klueppelberg
Hematology Oncology | Oncology
Distinguished in Chronic Myelogenous Leukemia (CML)
Dr. Horst U. Klueppelberg
Hematology Oncology | Oncology

Banner Cancer Center Specialists LLC

2946 E Banner Gateway Dr, 
Gilbert, AZ 
 (37.2 miles away)
480-256-6444
Languages Spoken:
English, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Horst Klueppelberg is a Hematologist Oncology specialist and an Oncologist in Gilbert, Arizona. Dr. Klueppelberg is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Marginal Zone Lymphoma (MZL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Richter Syndrome. Dr. Klueppelberg is currently accepting new patients.

Distinguished in Chronic Myelogenous Leukemia (CML)
Dr. Jeanne M. Palmer
Hematology Oncology | Transplant Surgery
Distinguished in Chronic Myelogenous Leukemia (CML)
Dr. Jeanne M. Palmer
Hematology Oncology | Transplant Surgery

Mayo Clinic Arizona

5777 E Mayo Blvd, Mayo Clinic Hospital, 
Phoenix, AZ 
 (27.4 miles away)
800-603-0558
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeanne Palmer is a Hematologist Oncology specialist and a Transplant Surgeon in Phoenix, Arizona. Dr. Palmer is rated as an Elite provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). Her top areas of expertise are Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Chronic Myelogenous Leukemia (CML)
Dr. Giraldo N. Kato
Oncology | Hematology
Advanced in Chronic Myelogenous Leukemia (CML)
Dr. Giraldo N. Kato
Oncology | Hematology

Honorhealth Ambulatory

2222 E Highland Ave, Suite 400, 
Phoenix, AZ 
 (19.4 miles away)
855-485-4673
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Giraldo Kato is an Oncologist and a Hematologist in Phoenix, Arizona. Dr. Kato is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Lung Cancer. Dr. Kato is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bryce's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 70 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile